An analysis has found that Mediana (041920) is accelerating the recovery of its core business performance as the inventory adjustment by customers that followed COVID-19 nears completion. While revenue recognition in its patient monitoring device business is being delayed beyond initial expectations, the number of contracted beds is growing rapidly, and the mid- to long-term growth driver remains valid.

■ Leading Investment Securities Maintains 'BUY'... Lowers Target Price to 15,000 Won

On the 27th, Leading Investment Securities maintained its 'BUY' investment opinion on Mediana (041920) and lowered its target price to 15,000 won. The reasons cited for the lowered target price include delays in the timing of new business revenue recognition and an overall decline in valuations in the KOSDAQ market. The firm explained that it adjusted the target price to a realistic level to reflect changes in market conditions.

■ Inventory Adjustment Nearing Completion... Core Business Improvement 'Faster Than Expected'

However, the key point of this analysis is that an improving trend is emerging in the company's core business. As the inventory adjustment accumulated at customers after COVID-19 enters its final stage, the pace of earnings recovery in the existing business is proving faster than expected.

■ Patient Monitoring Devices: Contracted Beds Increasing... Timing of Revenue Recognition Is Key

The patient monitoring device business is cited as a major variable for future performance. Although the timing of actual revenue recognition is being delayed, the number of contracted beds itself is increasing rapidly, expanding the business foundation. Whether contracted volumes are sequentially reflected in revenue going forward is expected to be the key variable for earnings growth.

■ Stock Price Hinges on Pace of Earnings Normalization and Revenue Conversion

Ultimately, Mediana's future stock price trajectory is expected to depend on the pace of earnings normalization in its core business and how quickly the growing contracts in the patient monitoring device business translate into actual revenue.

[Stock prices can exhibit heightened volatility depending on corporate performance, industry conditions, merger terms, market supply and demand, and other factors. Securities firms' analyses and forecasts may differ from actual future results and do not guarantee returns on any particular stock. Before making investment decisions, it is necessary to comprehensively review the company's official disclosures, financial condition, and business progress. This article is not intended to solicit the purchase or sale of any particular stock. This article was written with AI assistance.]